“Starting up NeuTherapeutics is so exciting because we are creating the path to bring the first regenerative therapeutic for Alzheimer’s disease to those who need it. We believe that treatment with allo will restore brain function and independence for patients,” says Dr. Roberta Brinton, a Regents Professor of pharmacology and neurology and a member of the BIO5 Institute.
Category Archives: AZBio News
Mayo Clinic Center for Regenerative Medicine
February 3, 2022 / Susan Buckles – Envisioning the future of regenerative medicine elicits images of an operating room that also is a manufacturing facility. Patients undergoing surgery could have immediate access to products biomanufactured within the operating room or even within their own bodies.
Understudied lncRNAs Could Help Enable Early Detection Of Potentially Deadly Liver Disease
TGen-Temple comprehensive review highlights recently discovered associations between long noncoding RNAs and specific diseasesContinue reading
Meet Zoey – AZBio’s Social Media and Communications Intern
Zoey Leipsic joined the AZBio Team in January of 2022 as our Social Media and Communications Intern. In her role, Zoey collects the latest news from our AZBio Member Companies and shares it via posts on AZBio.org as well as on AZBio’s social media accounts so that more people can learn about the important work you do.Continue reading
Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity
Paris, February 3, 2022. Sanofi today unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019.Continue reading
Perkins Coie Office Hours for AZBio
Perkins Coie attorneys are available to answer questions or discuss legal challenges pertaining to intellectual property and corporate issues that may arise for AZBio Members during “AZBio Office Hours”
PathogenDx Announces the CE Marking of Its Next-Generation COVID-19 Testing Technology for the Simultaneous Detection of SARS-CoV-2 (COVID-19) and Its Variants
The Technology Provides Medical Laboratories with a Rapid (6 hours), Affordable and Accurate Test for the Detection of SARS-CoV-2 (“COVID-19”) and its Variants (“VOC”) and (“VOI”) without Sequencing.
President Biden Reignites Cancer Moonshot to End Cancer as We Know It
Biden-Harris Administration Sets Goal of Reducing Cancer Death Rate by at least 50 Percent Over the Next 25 Years, and Improving the Experience of Living with and Surviving Cancer
Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models
TUCSON, AZ / ACCESSWIRE / February 1, 2022 / Aqualung Therapeutics, an early-stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for unchecked inflammation, a characteristic of serious acute diseases; has published a study in Scientific Reports (Tadeo Bermudez lead author) highlighting the effectiveness of the eNAMPT-neutralizing ALT-100 monoclonal antibody (mAb)in reducing Acute Respiratory Distress Syndrome (ARDS)/Ventilator Induced Lung Injury (VILI) symptoms in both rat and porcine animal models.
Continue reading
C-Path and the European Joint Programme on Rare Diseases to Expand Global Impact and Partnership
PARIS, France and TUCSON, Ariz., U.S., February 1, 2022 — Critical Path Institute (C-Path), an independent global nonprofit organization, and the European Joint Programme on Rare Diseases (EJP RD), an initiative that has received funding from the European Union’s Horizon 2020 research and innovation programme, have announced a collaboration to advance technologies and methodologies that are fit for regulatory purposes to further global rare disease research and drug development.Continue reading